P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.1593 ◽

2019 ◽

Vol 14 (10) ◽

pp. S744

Author(s):

J. Lee ◽

J. Chaft ◽

A. Nicholas ◽

G. Patterson ◽

S. Waqar ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Surgical Outcomes ◽

Phase Ii Trial ◽

Multicenter Phase

Download Full-text

Comparison of surgical outcomes among different methods of esophagojejunostomy in laparoscopic total gastrectomy for clinical stage I proximal gastric cancer: results of a single-arm multicenter phase II clinical trial in Korea, KLASS 03

Surgical Endoscopy ◽

10.1007/s00464-020-07480-0 ◽

2020 ◽

Author(s):

Han-Kwang Yang ◽

Woo Jin Hyung ◽

Sang-Uk Han ◽

Young-Jun Lee ◽

Joong-Min Park ◽

...

Keyword(s):

Gastric Cancer ◽

Clinical Trial ◽

Total Gastrectomy ◽

Phase Ii ◽

Surgical Outcomes ◽

Clinical Stage ◽

Laparoscopic Total Gastrectomy ◽

Stage I ◽

Proximal Gastric Cancer ◽

Multicenter Phase

Download Full-text

Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2009.01.035 ◽

2009 ◽

Vol 208 (5) ◽

pp. 906-914 ◽

Author(s):

John A. Olson ◽

G. Thomas Budd ◽

Lisa A. Carey ◽

Lyndsay A. Harris ◽

Laura J. Esserman ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Surgical Outcomes ◽

Phase Ii Trial ◽

Inhibitor Therapy ◽

Breast Cancer Patients ◽

Aromatase Inhibitor Therapy ◽

Multicenter Phase

Download Full-text

An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer

Zeitschrift für Gastroenterologie ◽

10.1055/s-0030-1263569 ◽

2010 ◽

Vol 48 (08) ◽

Author(s):

M Moehler ◽

J Hartmann ◽

F Lordick ◽

S Al-Batran ◽

P Reimer ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Gastric Cancer ◽

Multicenter Phase

Download Full-text

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

Faculty Opinions recommendation of Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157701.617915 ◽

2009 ◽

Author(s):

John Newell-Price ◽

Miguel Debono

Keyword(s):

Phase Ii ◽

Cushing’S Disease ◽

Phase Ii Trial ◽

Somatostatin Analog ◽

Cushing's Disease ◽

Multicenter Phase

Download Full-text

Faculty Opinions recommendation of A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718113892.793485442 ◽

2013 ◽

Author(s):

Luca Persani

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Multicenter Phase ◽

Histologic Subtypes ◽

Metastatic Thyroid Cancer

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793486222 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

Cancer ◽

10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9 ◽

1999 ◽

Vol 85 (4) ◽

pp. 786-795 ◽

Author(s):

Mace L. Rothenberg ◽

John V. Cox ◽

Russell F. DeVore ◽

John D. Hainsworth ◽

Richard Pazdur ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Multicenter Phase ◽

Previously Treated

Download Full-text

UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Hematological Oncology ◽

10.1002/hon.31_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

A. Pulsoni ◽

M. E. Tosti ◽

S. Ferrero ◽

S. Luminari ◽

A. Dondi ◽

...

Keyword(s):

Follicular Lymphoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Stage ◽

Multicenter Phase

Download Full-text

265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.259 ◽

2020 ◽

Vol 31 ◽

pp. S1347

Author(s):

Y. Chi ◽

M. Gao ◽

Y. Zhang ◽

F. Shi ◽

Y. Cheng ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Differentiated Thyroid Carcinoma ◽

Double Blind ◽

Multicenter Phase

Download Full-text